Analysts at Oppenheimer provided their outlook on NeuBase Therapeutics, Inc. (NASDAQ:NBSE) following Q4 results announcement and their virtual call with the management.

The company recently nominated the development candidate for its lead, NT0200 program in Myotonic Dystophy 1 (DM1) and started CMC scale-up to support IND-enabling studies and multi-dose Phase 1/2 clinical trials.

According to the brokerage further preclinical data updates are expected in 2022 in Huntington's Disease (HD) program. The company is also advancing its oncology program targeting KRAS G12D/ G12V mutations to in vivo pharmacology studies.

The brokerage maintained its bullish view given the company’s transformation from a research-stage to a development-stage company and the lead candidate poised to enter the clinic in 2022.